Trial Profile
Perimetrical Findings in the double frequency perimetry (PDT) in the treatment of branch vein with Lucentis (Ranibizumab)
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Jan 2020
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Branch retinal vein occlusion; Retinal oedema
- Focus Therapeutic Use
- 19 Sep 2016 New trial record